phase 2_completion
saveArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Prostate Cancer
Data sources
globaldata
Found something off?
drug timeline · 8
- phase 0 trial completionDana-Farber Cancer Institute Inc — atezolizumab (Phase 0 Trial Completion)Apr 29, 2026 · 162d ago
- approvalTECENTRIQ (ATEZOLIZUMAB) — FDA approvalNov 17, 2025 · 325d ago
- approvalTECENTRIQ (ATEZOLIZUMAB) — FDA approvalOct 2, 2025 · 371d ago
- approvalTECENTRIQ (ATEZOLIZUMAB) — FDA approvalAug 18, 2025 · 416d ago
- approvalTECENTRIQ (ATEZOLIZUMAB) — FDA approvalApr 22, 2024 · 899d ago
- approvalTECENTRIQ (ATEZOLIZUMAB) — FDA approvalMay 12, 2023 · 1245d ago
- approvalTECENTRIQ (ATEZOLIZUMAB) — FDA approvalMay 12, 2023 · 1245d ago
- approvalTECENTRIQ (ATEZOLIZUMAB) — FDA approvalDec 9, 2022 · 1399d ago
same company · ±60 days · 1
related news · 5
- endpointsDesign Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from China
- oncliveDr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC
- oncliveFDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer
- oncliveTrack the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
- oncliveSimlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC
🐶 often sniffed alongside
top 8- drugTECENTRIQ178 co-mentions · 46 sources
- tagApproval176 co-mentions · 44 sources
- companyGenentech Inc88 co-mentions · 44 sources
- drugTECENTRIQ HYBREZA20 co-mentions · 5 sources
- drug(atezolizumab + hyaluronidase (human recombinant))10 co-mentions · 5 sources
- tagOncology5 co-mentions · 2 sources
- companyDana-Farber Cancer Institute Inc1 co-mentions · 1 sources
- tagHepatology1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that